Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if salsalate, an Nuclear factor-kappaB (NF-κB) mediated inflammation inhibitor, or carvedilol, an α- and β-blocker, will protect against free fatty acid induced hypertension, insulin resistance, endothelial dysfunction, inflammation and oxidative stress, and autonomic dysfunction in obese normotensive subjects.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Emory University
• Collaborator: American Diabetes Association
• Treatments: Carvedilol; Salicylsalicylic acid; Sodium Salicylate; Soybean oil, phospholipid emulsion

Criteria

Inclusion Criteria:

• Males or females

• Obese subjects (body mass index (BMI) ≥ 30 kg/m^2)

• 18 and 65 years

• Blood pressure reading < 140/80 mm Hg and no prior history of hypertension

Exclusion Criteria:

• History of diabetes mellitus

• History of hypertension

• Fasting triglyceride levels > 250 mg/dL

• Liver disease (ALT 2.5x > upper limit of normal)

• Serum creatinine ≥1.5 mg/dL

• Smokers, drug or alcohol abuse

• Mental condition rendering the subject unable to understand the scope and possible consequences of the study

• Female subjects who are pregnant or breast feeding